Investor Relations

Conversion Right Extended on OPKO 3.0% Convertible Senior Notes more »

OPKO Health to Present at the Ladenburg Thalmann 2015 Healthcare Conference more »

OPKO Health Announces Global License Agreement for the Discovery of Novel Antimicrobials more »

OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant) more »

Conferences & Events

Upcoming Events
Details on upcoming events are not yet available.

Archived Event
Sep 24, 2015 OPKO Health Corporate Presentation – September 24, 2015
PDF View Presentation 702.3 KB